Predisposition for Disrepair in the Aged Lung
Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is a devastating progressive lung disease with an average survival of only 3 to 5 years. The mechanisms underlying the initiation and progression of IPF are poorly understood, and treatments available have only modest effect on disease progre...
Gespeichert in:
Veröffentlicht in: | The American journal of the medical sciences 2012-07, Vol.344 (1), p.41-51 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 51 |
---|---|
container_issue | 1 |
container_start_page | 41 |
container_title | The American journal of the medical sciences |
container_volume | 344 |
creator | Sueblinvong, Viranuj, MD Neujahr, David C., MD Todd Mills, S., BS Roser-Page, Susanne, BS Guidot, David, MD Rojas, Mauricio, MD Ritzenthaler, Jeffrey D., MS Roman, Jesse, MD |
description | Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is a devastating progressive lung disease with an average survival of only 3 to 5 years. The mechanisms underlying the initiation and progression of IPF are poorly understood, and treatments available have only modest effect on disease progression. Interestingly, the incidence of IPF is approximately 60 times more common in individuals aged 75 years and older, but the mechanism by which aging promotes fibrosis is unclear. The authors hypothesized that aged lungs have a profibrotic phenotype that render it susceptible to disrepair after injury. Methods Young and old mice were treated with bleomycin to examine disrepair in the aged lung. In addition, uninjured young and old mouse lungs were analyzed for transforming growth factor-beta 1 (TGF-β1) production, extracellular matrix composition and lung fibroblast phenotype. Lung fibroblasts were treated with a DNA methyltransferase inhibitor to examine the potential epigenetic mechanisms involved in age-associated phenotypic alterations. Results The lungs of old mice showed worse fibrosis after bleomycin-induced injury compared with the lungs from young mice. At baseline, aged lungs expressed a profibrotic phenotype characterized by increased mRNA expression for fibronectin extracellular domain A (Fn-EDA) and the matrix metalloproteinases (MMPs) MMP-2 and MMP-9. Old lungs also expressed higher levels of TGF-β receptor 1 and TGF-β1 mRNA, protein and activity as determined by increased Smad3 expression, protein phosphorylation and DNA binding. Lung fibroblasts harvested from aged lungs showed reduced expression of the surface molecule Thy-1, a finding also implicated in lung fibrosis; the latter did not seem related to Thy-1 gene methylation. Conclusion Altogether, aged lungs manifest a profibrotic phenotype characterized by enhanced fibronectin extracellular domain A and MMP expression and increased TGF-β1 expression and signaling and are populated by Thy-1–negative fibroblasts, all implicated in the pathogenesis of lung fibrosis. |
doi_str_mv | 10.1097/MAJ.0b013e318234c132 |
format | Article |
fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3395069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002962915309198</els_id><sourcerecordid>S0002962915309198</sourcerecordid><originalsourceid>FETCH-LOGICAL-c665t-2c8bab6e46e9a043a51e24dd12ffe5a3dc136c43fe0f4eba7ddc342f3db225033</originalsourceid><addsrcrecordid>eNqFkUtPHDEQhK0oUdiQ_IMIzYXjkLbbnh1fkFY88tBGQSI5Wx67vRgWz8qeReLfxysIJFxy8sFV1d1fMfaRwxEHPf_0ffHtCAbgSMh7gdJxFK_YjCvsW6E1vGYzABCt7oTeY-9KuQbgouf4lu0JwecIUs1Ye5HJx7IZS5zimJow5uY0lkwbG3MTUzNdUbNYkW-W27R6z94Euy704fHdZ7_Oz36efGmXPz5_PVksW9d1amqF6wc7dCQ70hYkWsVJSO-5CIGURV937ZzEQBAkDXbuvUMpAvpBCAWI--z4IXezHW7JO0pTtmuzyfHW5nsz2mj-_UnxyqzGO4OoFXS6BsiHAJfHUq8JT14OZofPVHzmJb5qO_h77pPpD68qOHwU2OLsOmSbXCzPug50r7R6PoAqpbtI2RQXKbnKOpObjB_j_zZ5GeDWMcU684buqVyP25xqA4abIgyYy13Vu6Zr_aC57vE3RwuiuQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Predisposition for Disrepair in the Aged Lung</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Sueblinvong, Viranuj, MD ; Neujahr, David C., MD ; Todd Mills, S., BS ; Roser-Page, Susanne, BS ; Guidot, David, MD ; Rojas, Mauricio, MD ; Ritzenthaler, Jeffrey D., MS ; Roman, Jesse, MD</creator><creatorcontrib>Sueblinvong, Viranuj, MD ; Neujahr, David C., MD ; Todd Mills, S., BS ; Roser-Page, Susanne, BS ; Guidot, David, MD ; Rojas, Mauricio, MD ; Ritzenthaler, Jeffrey D., MS ; Roman, Jesse, MD</creatorcontrib><description>Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is a devastating progressive lung disease with an average survival of only 3 to 5 years. The mechanisms underlying the initiation and progression of IPF are poorly understood, and treatments available have only modest effect on disease progression. Interestingly, the incidence of IPF is approximately 60 times more common in individuals aged 75 years and older, but the mechanism by which aging promotes fibrosis is unclear. The authors hypothesized that aged lungs have a profibrotic phenotype that render it susceptible to disrepair after injury. Methods Young and old mice were treated with bleomycin to examine disrepair in the aged lung. In addition, uninjured young and old mouse lungs were analyzed for transforming growth factor-beta 1 (TGF-β1) production, extracellular matrix composition and lung fibroblast phenotype. Lung fibroblasts were treated with a DNA methyltransferase inhibitor to examine the potential epigenetic mechanisms involved in age-associated phenotypic alterations. Results The lungs of old mice showed worse fibrosis after bleomycin-induced injury compared with the lungs from young mice. At baseline, aged lungs expressed a profibrotic phenotype characterized by increased mRNA expression for fibronectin extracellular domain A (Fn-EDA) and the matrix metalloproteinases (MMPs) MMP-2 and MMP-9. Old lungs also expressed higher levels of TGF-β receptor 1 and TGF-β1 mRNA, protein and activity as determined by increased Smad3 expression, protein phosphorylation and DNA binding. Lung fibroblasts harvested from aged lungs showed reduced expression of the surface molecule Thy-1, a finding also implicated in lung fibrosis; the latter did not seem related to Thy-1 gene methylation. Conclusion Altogether, aged lungs manifest a profibrotic phenotype characterized by enhanced fibronectin extracellular domain A and MMP expression and increased TGF-β1 expression and signaling and are populated by Thy-1–negative fibroblasts, all implicated in the pathogenesis of lung fibrosis.</description><identifier>ISSN: 0002-9629</identifier><identifier>EISSN: 1538-2990</identifier><identifier>DOI: 10.1097/MAJ.0b013e318234c132</identifier><identifier>PMID: 22173045</identifier><identifier>CODEN: AJMSA9</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>Aging ; Animals ; Biological and medical sciences ; Bleomycin - chemistry ; Extracellular matrix ; Extracellular Matrix - metabolism ; Extracellular Matrix - pathology ; Fibroblasts - metabolism ; Fibroblasts - pathology ; Fibronectins - metabolism ; General aspects ; Idiopathic Pulmonary Fibrosis - chemically induced ; Idiopathic Pulmonary Fibrosis - pathology ; Injury ; Internal Medicine ; Lung - pathology ; Lung fibroblast ; Lung fibrosis ; Matrix Metalloproteinase 2 - metabolism ; Matrix Metalloproteinase 9 - metabolism ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Models, Animal ; Pneumology ; Protein-Serine-Threonine Kinases - metabolism ; Receptors, Transforming Growth Factor beta - metabolism ; Respiratory system : syndromes and miscellaneous diseases ; RNA, Messenger - metabolism ; Smad3 Protein - metabolism ; Transforming Growth Factor beta1 - metabolism</subject><ispartof>The American journal of the medical sciences, 2012-07, Vol.344 (1), p.41-51</ispartof><rights>Southern Society for Clinical Investigation</rights><rights>2012 Southern Society for Clinical Investigation</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c665t-2c8bab6e46e9a043a51e24dd12ffe5a3dc136c43fe0f4eba7ddc342f3db225033</citedby><cites>FETCH-LOGICAL-c665t-2c8bab6e46e9a043a51e24dd12ffe5a3dc136c43fe0f4eba7ddc342f3db225033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26098595$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22173045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sueblinvong, Viranuj, MD</creatorcontrib><creatorcontrib>Neujahr, David C., MD</creatorcontrib><creatorcontrib>Todd Mills, S., BS</creatorcontrib><creatorcontrib>Roser-Page, Susanne, BS</creatorcontrib><creatorcontrib>Guidot, David, MD</creatorcontrib><creatorcontrib>Rojas, Mauricio, MD</creatorcontrib><creatorcontrib>Ritzenthaler, Jeffrey D., MS</creatorcontrib><creatorcontrib>Roman, Jesse, MD</creatorcontrib><title>Predisposition for Disrepair in the Aged Lung</title><title>The American journal of the medical sciences</title><addtitle>Am J Med Sci</addtitle><description>Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is a devastating progressive lung disease with an average survival of only 3 to 5 years. The mechanisms underlying the initiation and progression of IPF are poorly understood, and treatments available have only modest effect on disease progression. Interestingly, the incidence of IPF is approximately 60 times more common in individuals aged 75 years and older, but the mechanism by which aging promotes fibrosis is unclear. The authors hypothesized that aged lungs have a profibrotic phenotype that render it susceptible to disrepair after injury. Methods Young and old mice were treated with bleomycin to examine disrepair in the aged lung. In addition, uninjured young and old mouse lungs were analyzed for transforming growth factor-beta 1 (TGF-β1) production, extracellular matrix composition and lung fibroblast phenotype. Lung fibroblasts were treated with a DNA methyltransferase inhibitor to examine the potential epigenetic mechanisms involved in age-associated phenotypic alterations. Results The lungs of old mice showed worse fibrosis after bleomycin-induced injury compared with the lungs from young mice. At baseline, aged lungs expressed a profibrotic phenotype characterized by increased mRNA expression for fibronectin extracellular domain A (Fn-EDA) and the matrix metalloproteinases (MMPs) MMP-2 and MMP-9. Old lungs also expressed higher levels of TGF-β receptor 1 and TGF-β1 mRNA, protein and activity as determined by increased Smad3 expression, protein phosphorylation and DNA binding. Lung fibroblasts harvested from aged lungs showed reduced expression of the surface molecule Thy-1, a finding also implicated in lung fibrosis; the latter did not seem related to Thy-1 gene methylation. Conclusion Altogether, aged lungs manifest a profibrotic phenotype characterized by enhanced fibronectin extracellular domain A and MMP expression and increased TGF-β1 expression and signaling and are populated by Thy-1–negative fibroblasts, all implicated in the pathogenesis of lung fibrosis.</description><subject>Aging</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bleomycin - chemistry</subject><subject>Extracellular matrix</subject><subject>Extracellular Matrix - metabolism</subject><subject>Extracellular Matrix - pathology</subject><subject>Fibroblasts - metabolism</subject><subject>Fibroblasts - pathology</subject><subject>Fibronectins - metabolism</subject><subject>General aspects</subject><subject>Idiopathic Pulmonary Fibrosis - chemically induced</subject><subject>Idiopathic Pulmonary Fibrosis - pathology</subject><subject>Injury</subject><subject>Internal Medicine</subject><subject>Lung - pathology</subject><subject>Lung fibroblast</subject><subject>Lung fibrosis</subject><subject>Matrix Metalloproteinase 2 - metabolism</subject><subject>Matrix Metalloproteinase 9 - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Models, Animal</subject><subject>Pneumology</subject><subject>Protein-Serine-Threonine Kinases - metabolism</subject><subject>Receptors, Transforming Growth Factor beta - metabolism</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><subject>RNA, Messenger - metabolism</subject><subject>Smad3 Protein - metabolism</subject><subject>Transforming Growth Factor beta1 - metabolism</subject><issn>0002-9629</issn><issn>1538-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtPHDEQhK0oUdiQ_IMIzYXjkLbbnh1fkFY88tBGQSI5Wx67vRgWz8qeReLfxysIJFxy8sFV1d1fMfaRwxEHPf_0ffHtCAbgSMh7gdJxFK_YjCvsW6E1vGYzABCt7oTeY-9KuQbgouf4lu0JwecIUs1Ye5HJx7IZS5zimJow5uY0lkwbG3MTUzNdUbNYkW-W27R6z94Euy704fHdZ7_Oz36efGmXPz5_PVksW9d1amqF6wc7dCQ70hYkWsVJSO-5CIGURV937ZzEQBAkDXbuvUMpAvpBCAWI--z4IXezHW7JO0pTtmuzyfHW5nsz2mj-_UnxyqzGO4OoFXS6BsiHAJfHUq8JT14OZofPVHzmJb5qO_h77pPpD68qOHwU2OLsOmSbXCzPug50r7R6PoAqpbtI2RQXKbnKOpObjB_j_zZ5GeDWMcU684buqVyP25xqA4abIgyYy13Vu6Zr_aC57vE3RwuiuQ</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Sueblinvong, Viranuj, MD</creator><creator>Neujahr, David C., MD</creator><creator>Todd Mills, S., BS</creator><creator>Roser-Page, Susanne, BS</creator><creator>Guidot, David, MD</creator><creator>Rojas, Mauricio, MD</creator><creator>Ritzenthaler, Jeffrey D., MS</creator><creator>Roman, Jesse, MD</creator><general>Elsevier Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20120701</creationdate><title>Predisposition for Disrepair in the Aged Lung</title><author>Sueblinvong, Viranuj, MD ; Neujahr, David C., MD ; Todd Mills, S., BS ; Roser-Page, Susanne, BS ; Guidot, David, MD ; Rojas, Mauricio, MD ; Ritzenthaler, Jeffrey D., MS ; Roman, Jesse, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c665t-2c8bab6e46e9a043a51e24dd12ffe5a3dc136c43fe0f4eba7ddc342f3db225033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aging</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bleomycin - chemistry</topic><topic>Extracellular matrix</topic><topic>Extracellular Matrix - metabolism</topic><topic>Extracellular Matrix - pathology</topic><topic>Fibroblasts - metabolism</topic><topic>Fibroblasts - pathology</topic><topic>Fibronectins - metabolism</topic><topic>General aspects</topic><topic>Idiopathic Pulmonary Fibrosis - chemically induced</topic><topic>Idiopathic Pulmonary Fibrosis - pathology</topic><topic>Injury</topic><topic>Internal Medicine</topic><topic>Lung - pathology</topic><topic>Lung fibroblast</topic><topic>Lung fibrosis</topic><topic>Matrix Metalloproteinase 2 - metabolism</topic><topic>Matrix Metalloproteinase 9 - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Models, Animal</topic><topic>Pneumology</topic><topic>Protein-Serine-Threonine Kinases - metabolism</topic><topic>Receptors, Transforming Growth Factor beta - metabolism</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><topic>RNA, Messenger - metabolism</topic><topic>Smad3 Protein - metabolism</topic><topic>Transforming Growth Factor beta1 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sueblinvong, Viranuj, MD</creatorcontrib><creatorcontrib>Neujahr, David C., MD</creatorcontrib><creatorcontrib>Todd Mills, S., BS</creatorcontrib><creatorcontrib>Roser-Page, Susanne, BS</creatorcontrib><creatorcontrib>Guidot, David, MD</creatorcontrib><creatorcontrib>Rojas, Mauricio, MD</creatorcontrib><creatorcontrib>Ritzenthaler, Jeffrey D., MS</creatorcontrib><creatorcontrib>Roman, Jesse, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of the medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sueblinvong, Viranuj, MD</au><au>Neujahr, David C., MD</au><au>Todd Mills, S., BS</au><au>Roser-Page, Susanne, BS</au><au>Guidot, David, MD</au><au>Rojas, Mauricio, MD</au><au>Ritzenthaler, Jeffrey D., MS</au><au>Roman, Jesse, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predisposition for Disrepair in the Aged Lung</atitle><jtitle>The American journal of the medical sciences</jtitle><addtitle>Am J Med Sci</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>344</volume><issue>1</issue><spage>41</spage><epage>51</epage><pages>41-51</pages><issn>0002-9629</issn><eissn>1538-2990</eissn><coden>AJMSA9</coden><abstract>Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is a devastating progressive lung disease with an average survival of only 3 to 5 years. The mechanisms underlying the initiation and progression of IPF are poorly understood, and treatments available have only modest effect on disease progression. Interestingly, the incidence of IPF is approximately 60 times more common in individuals aged 75 years and older, but the mechanism by which aging promotes fibrosis is unclear. The authors hypothesized that aged lungs have a profibrotic phenotype that render it susceptible to disrepair after injury. Methods Young and old mice were treated with bleomycin to examine disrepair in the aged lung. In addition, uninjured young and old mouse lungs were analyzed for transforming growth factor-beta 1 (TGF-β1) production, extracellular matrix composition and lung fibroblast phenotype. Lung fibroblasts were treated with a DNA methyltransferase inhibitor to examine the potential epigenetic mechanisms involved in age-associated phenotypic alterations. Results The lungs of old mice showed worse fibrosis after bleomycin-induced injury compared with the lungs from young mice. At baseline, aged lungs expressed a profibrotic phenotype characterized by increased mRNA expression for fibronectin extracellular domain A (Fn-EDA) and the matrix metalloproteinases (MMPs) MMP-2 and MMP-9. Old lungs also expressed higher levels of TGF-β receptor 1 and TGF-β1 mRNA, protein and activity as determined by increased Smad3 expression, protein phosphorylation and DNA binding. Lung fibroblasts harvested from aged lungs showed reduced expression of the surface molecule Thy-1, a finding also implicated in lung fibrosis; the latter did not seem related to Thy-1 gene methylation. Conclusion Altogether, aged lungs manifest a profibrotic phenotype characterized by enhanced fibronectin extracellular domain A and MMP expression and increased TGF-β1 expression and signaling and are populated by Thy-1–negative fibroblasts, all implicated in the pathogenesis of lung fibrosis.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>22173045</pmid><doi>10.1097/MAJ.0b013e318234c132</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9629 |
ispartof | The American journal of the medical sciences, 2012-07, Vol.344 (1), p.41-51 |
issn | 0002-9629 1538-2990 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3395069 |
source | Journals@Ovid Ovid Autoload; MEDLINE; Alma/SFX Local Collection |
subjects | Aging Animals Biological and medical sciences Bleomycin - chemistry Extracellular matrix Extracellular Matrix - metabolism Extracellular Matrix - pathology Fibroblasts - metabolism Fibroblasts - pathology Fibronectins - metabolism General aspects Idiopathic Pulmonary Fibrosis - chemically induced Idiopathic Pulmonary Fibrosis - pathology Injury Internal Medicine Lung - pathology Lung fibroblast Lung fibrosis Matrix Metalloproteinase 2 - metabolism Matrix Metalloproteinase 9 - metabolism Medical sciences Mice Mice, Inbred C57BL Models, Animal Pneumology Protein-Serine-Threonine Kinases - metabolism Receptors, Transforming Growth Factor beta - metabolism Respiratory system : syndromes and miscellaneous diseases RNA, Messenger - metabolism Smad3 Protein - metabolism Transforming Growth Factor beta1 - metabolism |
title | Predisposition for Disrepair in the Aged Lung |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T20%3A31%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predisposition%20for%20Disrepair%20in%20the%20Aged%20Lung&rft.jtitle=The%20American%20journal%20of%20the%20medical%20sciences&rft.au=Sueblinvong,%20Viranuj,%20MD&rft.date=2012-07-01&rft.volume=344&rft.issue=1&rft.spage=41&rft.epage=51&rft.pages=41-51&rft.issn=0002-9629&rft.eissn=1538-2990&rft.coden=AJMSA9&rft_id=info:doi/10.1097/MAJ.0b013e318234c132&rft_dat=%3Celsevier_pubme%3ES0002962915309198%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22173045&rft_els_id=S0002962915309198&rfr_iscdi=true |